Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2.

Winter E, Lecerf-Schmidt F, Gozzi G, Peres B, Lightbody M, Gauthier C, Ozvegy-Laczka C, Szakacs G, Sarkadi B, Creczynski-Pasa TB, Boumendjel A, Di Pietro A.

J Med Chem. 2013 Dec 27;56(24):9849-60. doi: 10.1021/jm401649j. Epub 2013 Dec 13.

PMID:
24304387
2.

Substituted chromones as highly potent nontoxic inhibitors, specific for the breast cancer resistance protein.

Valdameri G, Genoux-Bastide E, Peres B, Gauthier C, Guitton J, Terreux R, Winnischofer SM, Rocha ME, Boumendjel A, Di Pietro A.

J Med Chem. 2012 Jan 26;55(2):966-70. doi: 10.1021/jm201404w. Epub 2012 Jan 6.

PMID:
22165858
3.

Symmetric bis-chalcones as a new type of breast cancer resistance protein inhibitors with a mechanism different from that of chromones.

Winter E, Devantier Neuenfeldt P, Chiaradia-Delatorre LD, Gauthier C, Yunes RA, Nunes RJ, Creczynski-Pasa TB, Di Pietro A.

J Med Chem. 2014 Apr 10;57(7):2930-41. doi: 10.1021/jm401879z. Epub 2014 Mar 24.

PMID:
24611893
4.

Piperazinobenzopyranones and phenalkylaminobenzopyranones: potent inhibitors of breast cancer resistance protein (ABCG2).

Boumendjel A, Nicolle E, Moraux T, Gerby B, Blanc M, Ronot X, Boutonnat J.

J Med Chem. 2005 Nov 17;48(23):7275-81.

PMID:
16279786
5.

Phenolic indeno[1,2-b]indoles as ABCG2-selective potent and non-toxic inhibitors stimulating basal ATPase activity.

Gozzi GJ, Bouaziz Z, Winter E, Daflon-Yunes N, Honorat M, Guragossian N, Marminon C, Valdameri G, Bollacke A, Guillon J, Pinaud N, Marchivie M, Cadena SM, Jose J, Le Borgne M, Di Pietro A.

Drug Des Devel Ther. 2015 Jul 3;9:3481-95. doi: 10.2147/DDDT.S84982. eCollection 2015.

6.

Flavonoid structure-activity studies identify 6-prenylchrysin and tectochrysin as potent and specific inhibitors of breast cancer resistance protein ABCG2.

Ahmed-Belkacem A, Pozza A, Muñoz-Martínez F, Bates SE, Castanys S, Gamarro F, Di Pietro A, Pérez-Victoria JM.

Cancer Res. 2005 Jun 1;65(11):4852-60.

7.

6-halogenochromones bearing tryptamine: one-step access to potent and highly selective inhibitors of breast cancer resistance protein.

Valdameri G, Genoux-Bastide E, Gauthier C, Peres B, Terreux R, Winnischofer SM, Rocha ME, Di Pietro A, Boumendjel A.

ChemMedChem. 2012 Jul;7(7):1177-80. doi: 10.1002/cmdc.201200154. Epub 2012 May 21. No abstract available.

PMID:
22615192
8.

New structure-activity relationships of chalcone inhibitors of breast cancer resistance protein: polyspecificity toward inhibition and critical substitutions against cytotoxicity.

Rangel LP, Winter E, Gauthier C, Terreux R, Chiaradia-Delatorre LD, Mascarello A, Nunes RJ, Yunes RA, Creczynski-Pasa TB, Macalou S, Lorendeau D, Baubichon-Cortay H, Ferreira-Pereira A, Di Pietro A.

Drug Des Devel Ther. 2013 Sep 30;7:1043-52. doi: 10.2147/DDDT.S46983. eCollection 2013.

9.

Synthesis and ABCG2 inhibitory evaluation of 5-N-acetylardeemin derivatives.

Hayashi D, Tsukioka N, Inoue Y, Matsubayashi Y, Iizuka T, Higuchi K, Ikegami Y, Kawasaki T.

Bioorg Med Chem. 2015 May 1;23(9):2010-23. doi: 10.1016/j.bmc.2015.03.017. Epub 2015 Mar 12.

PMID:
25835358
10.

Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.

Jabor Gozzi G, Bouaziz Z, Winter E, Daflon-Yunes N, Aichele D, Nacereddine A, Marminon C, Valdameri G, Zeinyeh W, Bollacke A, Guillon J, Lacoudre A, Pinaud N, Cadena SM, Jose J, Le Borgne M, Di Pietro A.

J Med Chem. 2015 Jan 8;58(1):265-77. doi: 10.1021/jm500943z. Epub 2014 Oct 16.

PMID:
25272055
11.

Investigation of quinazolines as inhibitors of breast cancer resistance protein (ABCG2).

Juvale K, Gallus J, Wiese M.

Bioorg Med Chem. 2013 Dec 15;21(24):7858-73. doi: 10.1016/j.bmc.2013.10.007. Epub 2013 Oct 17.

PMID:
24184213
12.

Methoxy stilbenes as potent, specific, untransported, and noncytotoxic inhibitors of breast cancer resistance protein.

Valdameri G, Pereira Rangel L, Spatafora C, Guitton J, Gauthier C, Arnaud O, Ferreira-Pereira A, Falson P, Winnischofer SM, Rocha ME, Tringali C, Di Pietro A.

ACS Chem Biol. 2012 Feb 17;7(2):322-30. doi: 10.1021/cb200435y. Epub 2011 Nov 11.

PMID:
22039929
13.

Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar.

Kühnle M, Egger M, Müller C, Mahringer A, Bernhardt G, Fricker G, König B, Buschauer A.

J Med Chem. 2009 Feb 26;52(4):1190-7. doi: 10.1021/jm8013822.

PMID:
19170519
14.

Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.

Pick A, Wiese M.

ChemMedChem. 2012 Apr;7(4):650-62. doi: 10.1002/cmdc.201100543. Epub 2012 Feb 22.

PMID:
22354538
15.

Breast cancer resistance protein (BCRP/ABCG2): new inhibitors and QSAR studies by a 3D linear solvation energy approach.

Nicolle E, Boccard J, Guilet D, Dijoux-Franca MG, Zelefac F, Macalou S, Grosselin J, Schmidt J, Carrupt PA, Di Pietro A, Boumendjel A.

Eur J Pharm Sci. 2009 Aug 12;38(1):39-46. doi: 10.1016/j.ejps.2009.05.012. Epub 2009 Jun 6.

PMID:
19501160
16.

Structure-activity relationships and quantitative structure-activity relationships for breast cancer resistance protein (ABCG2).

Gandhi YA, Morris ME.

AAPS J. 2009 Sep;11(3):541-52. doi: 10.1208/s12248-009-9132-1. Epub 2009 Jul 24. Review.

17.

Investigation of chalcones as selective inhibitors of the breast cancer resistance protein: critical role of methoxylation in both inhibition potency and cytotoxicity.

Valdameri G, Gauthier C, Terreux R, Kachadourian R, Day BJ, Winnischofer SM, Rocha ME, Frachet V, Ronot X, Di Pietro A, Boumendjel A.

J Med Chem. 2012 Apr 12;55(7):3193-200. doi: 10.1021/jm2016528. Epub 2012 Apr 2.

18.

Acridone derivatives: design, synthesis, and inhibition of breast cancer resistance protein ABCG2.

Boumendjel A, Macalou S, Ahmed-Belkacem A, Blanc M, Di Pietro A.

Bioorg Med Chem. 2007 Apr 15;15(8):2892-7. Epub 2007 Feb 13.

PMID:
17317193
19.

Nonprenylated rotenoids, a new class of potent breast cancer resistance protein inhibitors.

Ahmed-Belkacem A, Macalou S, Borrelli F, Capasso R, Fattorusso E, Taglialatela-Scafati O, Di Pietro A.

J Med Chem. 2007 Apr 19;50(8):1933-8. Epub 2007 Mar 7.

PMID:
17341062
20.

A global drug inhibition pattern for the human ATP-binding cassette transporter breast cancer resistance protein (ABCG2).

Matsson P, Englund G, Ahlin G, Bergström CA, Norinder U, Artursson P.

J Pharmacol Exp Ther. 2007 Oct;323(1):19-30. Epub 2007 Jul 6.

Items per page

Supplemental Content

Write to the Help Desk